Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AB248 |
Trade Name | |
Synonyms | AB-248|AB 248 |
Drug Descriptions |
AB248 is a fusion protein comprised of an anti-CD8 antibody fused to an IL-2 mutein, which preferentially targets CD8+ T-lymphocytes, potentially resulting in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 3518). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AB248 | AB248 | 0 | 1 |
AB248 + Pembrolizumab | AB248 Pembrolizumab | 0 | 1 |